pronounced: Vel-Kade

Velcade® (bortezomib) is a targeted therapy used to treat multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells. By blocking proteasomes, Velcade disrupts cancer cell function, leading to cell death, especially in rapidly growing cancer cells. It is often used in combination with other treatments, such as chemotherapy or immunotherapy, to improve treatment effectiveness.